Beisi Bio Secures ￥100 Million in Angel Round of Financing

(VCBeat) July. 26, 2021 -- Biotechnology company Zhuhai Beisi Angke ("Beisi Bio") recently completed an angel round financing of nearly 100 million yuan, with participation from Highlight Capital, Virtus Inspire Ventures and Panacea Venture. Hengqin Financial Investment also joined in this round of investment. The funds raised will mainly be used for the upgrade of Beisi Bio's unique gene-editing platform of natural killer (NK) cells and the gene therapy platform, product research and development, patent application and related team building.

Beisi Bio was officially established in April this year. The company was founded by Dr. Tianhong Xu, a clinician, researcher, entrepreneur and venture capitalist with 20 years of experience in the biomedical field, focusing on the development of novel gene-edited NK cell therapy products and gene therapy products. Dr. Xu received his Ph.D. in human and molecular genetics from Baylor College of Medicine in the United States. The core team of Beisi Bio consists of experts who have been focused on NK cell therapy for 15 years, leading gene editing and base editing experts, and experts who have been in the cell therapy industry and clinical trials for 20 years respectively.

Beisi Bio has a series of core technologies, patents and know-how in the field of NK cells and gene editing. It has established a comprehensive platform for genetic engineering modification of NK cells and completed the proof of concept. The current development pipeline includes a number of first-in-class general-purpose cell therapy products that are the first of their kind in the world, with indications for a variety of solid tumors, including lung cancer, liver cancer, and glioma, as well as for unmet therapeutic needs in hematologic tumors.

HLC is a health industry-focused fund. It is dedicated to investing in leading life science enterprises that provide innovative products and services to advance diagnosis and treatment of diseases and to promote healthy living. With extensive experience, the company has established a strong presence across sub-sectors such as biotechnology (innovative therapeutics, CRO/CMO, etc.), medical technology (medical devices, IVD, etc.) and consumer health (hospital chains, personal care, etc.).

Virtus Inspire Ventures invests in TMT and MedTech companies in China, the U.S., and Israel. The firm invests in early-stage cross border technology companies. It helps portfolio companies get into massive and fast-growing markets of China and Asia, and assist Chinese companies to expand abroad.